PKM2 is a potential prognostic biomarker and related to immune infiltration in lung cancer.
PKM2 is a potential prognostic biomarker and related to immune infiltration in lung cancer.
复制标题
PKM2是一种潜在的预后生物标志物，与肺癌的免疫浸润有关。
DOI：
10.1038/s41598-023-49558-4
复制
发表时间：
2023-12-14
影响因子：
4.6
通讯作者：
Ma, Yongxin
中科院分区：
文献类型：
--
作者：
Yin, Lan;Shi, Jiaying;Zhang, Jingfei;Lin, Xinyu;Jiang, Wenhao;Zhu, Yingchuan;Song, Yue;Lu, Yilu;Ma, Yongxin
丙酮酸激酶M2（PKM 2）是丙酮酸激酶的一个亚型，在糖酵解的最后一步起着关键作用。它参与调节肿瘤微环境和加速肿瘤进展。然而，PKM 2表达与肺癌预后及免疫浸润的关系尚不清楚。在这项研究中，我们分析了PKM 2在泛癌中的表达，并通过使用多个在线数据库，包括Gent 2，肿瘤免疫评估资源（TIMER），基因表达谱交互分析（GEPIA），PrognoScan，Kaplan-Meier曲线和人类蛋白质图谱（HPA），研究其与肺癌预后和免疫细胞浸润的关系。结果表明，PKM 2在肿瘤组织中的表达高于包括肺癌在内的大多数癌症的邻近正常组织。预后分析表明，PKM 2高表达与肺癌患者的总体预后较差，尤其是肺腺癌（LUAD）。值得注意的是，PKM 2在LUAD中与B细胞和CD 4 + T细胞表现出强相关性;在肺鳞状细胞癌（LUSC）中与B细胞、CD 8 + T细胞、CD 4+细胞和巨噬细胞表现出强相关性。此外，PKM 2表达与LUAD和LUSC中免疫细胞标志物的表达呈显著负相关。这些发现表明PKM 2可以作为肺癌的一个有前途的预后生物标志物，并提供了其在调节免疫细胞浸润中的重要作用的见解。
Pyruvate kinase M2 (PKM2), a subtype of pyruvate kinase, plays a crucial role as a key enzyme in the final step of glycolysis. It is involved in regulating the tumor microenvironment and accelerating tumor progression. However, the relationship between PKM2 expression and the prognosis and immune infiltration remains unclear in lung cancer. In this study, we analyzed PKM2 expression in pan-cancer, and investigated its association with prognosis and immune cell infiltration of lung cancer by using multiple online databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), PrognoScan, Kaplan–Meier plotter, and The Human Protein Atlas (HPA). The results showed that PKM2 expression is elevated in tumor tissues compared with the adjacent normal tissues of most cancers, including lung cancer. Prognostic analysis indicated that high expression of PKM2 was associated with poorer prognosis in overall lung cancer patients, especially in lung adenocarcinoma (LUAD). Notably, PKM2 exhibited a strong correlation with B cells and CD4+ T cells in LUAD; and with B cells, CD8+ T cells, CD4+ cells, and macrophages in lung squamous cell carcinoma (LUSC). Furthermore, PKM2 expression displayed a significant negative correlation with the expression of immune cell markers in both LUAD and LUSC. These findings suggested that PKM2 could serve as a promising prognostic biomarker for lung cancer and provided insights into its essential role in modulating the immune cell infiltration.
登录
查看更多内容
GEPIA：用于癌症和正常基因表达谱和交互式分析的网络服务器。
影响因子：
14.9
作者：
Tang Z;Li C;Kang B;Gao G;Li C;Zhang Z
通讯作者：
Zhang Z
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
5.2
作者：
Sinha A;Zou Y;Patel AS;Yoo S;Jiang F;Sato T;Kong R;Watanabe H;Zhu J;Massion PP;Borczuk AC;Powell CA
通讯作者：
Powell CA
影响因子：
7.3
作者：
Gui, Dan Y.;Lewis, Caroline A.;Vander Heiden, Matthew G.
通讯作者：
Vander Heiden, Matthew G.
肿瘤微环境中癌症相关成纤维细胞和免疫细胞之间的串扰：新发现和未来前景。
影响因子：
37.3
作者：
Mao X;Xu J;Wang W;Liang C;Hua J;Liu J;Zhang B;Meng Q;Yu X;Shi S
通讯作者：
Shi S